Gyre Therapeutics — Q3 2026 Earnings Summary

Gyre Therapeutics reported third-quarter 2026 revenue of $32.9 million, driven primarily by sales of its flagship product ETUARY in China, while full-year revenue guidance remains between $100.5 million and $111.0 million. The company incurred a net loss of $2.5 million for the quarter, a shift from the previous year's net income, largely due to increased operating expenses and transaction costs associated with the acquisition of Cullgen. Key pipeline updates include the completion of an NMPA on-site inspection for the F351 New Drug Application, with a regulatory decision anticipated by the end of 2026 or early 2027. Additionally, the company plans to initiate Phase 2 studies for CG001419 in cancer pain and expects to submit IND applications for dual-degrader programs around mid-2027.